Fiche société
Mostafa Bahaa
Traitements, essais et publications liés.
Traitements1programmes
Essais1liés
Publications3liées
SourceDBlocale
Traitements
1| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| MontelukastParkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease (AD). Clinical manifestations of PD can vary, but a formal diagnosis relies on the presence of bradykinesia with rigidity and/or rest tremor according to Movement Disorder Society (MDS) criteria for PD. Non-motor symptoms, such as hyposmia, constipation, depression, and rapid eye movement (REM) sleep behavior disorder, are common and can in many cases manifest before classical motor symptoms. In later years, more emphasis has been put on non-motor symptoms, especially in the early stages of PD and which is evident in the proposed prodromal PD criterion by MDS. | Parkinson | Phase 2/3 | Traitement symptomatique | Egypt | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| levodopa-carbidopa | Parkinson | Phase 2/3 | NCT06113640 | Montelukast in Parkinson Disease | COMPLETED |
Publications
3| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Montelukast | Not always a good night's sleep: A global pharmacovigilance risk profiling of drug-induced sleep disorders. | Sleep medicine | ||
| Montelukast | Leukotriene receptor antagonists inhibit SLC19A1 and SLC46A1-mediated transport of folic acid and antifolates. | Chemico-biological interactions | ||
| Montelukast | The dual role of leukotrienes in the tumor microenvironment: balancing pro-tumorigenic and anti-tumor immunity. | Cancer biology & therapy |